Svetlana Lucas insider trades
Open-market stock purchases and sales by Svetlana Lucas, Director at Jasper Therapeutics, Inc, from SEC Form 4 filings since Jun 28, 2019.
Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging -27%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jul 31, 2026 | JSPR Jasper Therapeutics, Inc | Bought (not open market) | — |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc | Bought | $45K |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc | Bought (not open market) | — |
| May 11, 2026 | ATYR aTYR PHARMA Inc | Bought (not open market) | — |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc | Bought (not open market) | — |